Literature DB >> 14984815

Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy.

Frederick Wolfe1, Kaleb Michaud.   

Abstract

PURPOSE: We sought to determine the frequency of heart failure in patients with rheumatoid arthritis, and to determine its predictors, particularly the use of anti-tumor necrosis factor (TNF) therapy.
METHODS: Rheumatoid arthritis (n = 13,171) and osteoarthritis (n = 2568) patients were studied during a 2-year period ending in June 2002. The diagnosis of heart failure was based on self-report or review of medical records. Propensity scores were used to adjust for the risk of anti-TNF (infliximab and etanercept) prescription.
RESULTS: Heart failure was more common among patients with rheumatoid arthritis (3.9% [n = 461]) than in those with osteoarthritis (2.3% [n = 87]), after adjusting for differences in demographic characteristics. Patients with rheumatoid arthritis had similar risk factors for heart failure (e.g., hypertension, prior myocardial infarction, diabetes, advanced age) as persons in population-based studies. Heart failure was significantly (P <0.05) less common in anti-TNF-treated patients (3.1% [180/5832]) than in the remaining patients (3.8% [281/7339]), even after adjusting for baseline differences. In the absence of pre-existing cardiovascular disease, the risk of heart failure was low (0.4% [24/6251]) and was not related to anti-TNF therapy.
CONCLUSION: Our results suggest that rheumatoid arthritis increases the risk of heart failure, which may be ameliorated by anti-TNF therapies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14984815     DOI: 10.1016/j.amjmed.2003.09.039

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  83 in total

Review 1.  Tumor necrosis factor-α signaling in macrophages.

Authors:  Narayanan Parameswaran; Sonika Patial
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2010       Impact factor: 1.807

2.  [Biologics and cardiovascular risk].

Authors:  I H Tarner; U Müller-Ladner; C Hamm
Journal:  Z Rheumatol       Date:  2010-10       Impact factor: 1.372

3.  [Recommendations for the management of ankylosing spodylitis after ASAS/EULAR. Evaluation in the German language area].

Authors:  J Braun; J Zochling; E Märker-Hermann; G Stucki; H Böhm; M Rudwaleit; H Zeidler; J Sieper
Journal:  Z Rheumatol       Date:  2006-12       Impact factor: 1.372

Review 4.  Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis.

Authors:  J Zochling; D van der Heijde; M Dougados; J Braun
Journal:  Ann Rheum Dis       Date:  2005-08-26       Impact factor: 19.103

5.  ASAS/EULAR recommendations for the management of ankylosing spondylitis.

Authors:  J Zochling; D van der Heijde; R Burgos-Vargas; E Collantes; J C Davis; B Dijkmans; M Dougados; P Géher; R D Inman; M A Khan; T K Kvien; M Leirisalo-Repo; I Olivieri; K Pavelka; J Sieper; G Stucki; R D Sturrock; S van der Linden; D Wendling; H Böhm; B J van Royen; J Braun
Journal:  Ann Rheum Dis       Date:  2005-08-26       Impact factor: 19.103

6.  Left ventricular systolic dysfunction in two patients with ankylosing spondylitis: What is the role of corticosteroids?

Authors:  Ahmad Amin; Mitra Chitsazan; Hossein Navid
Journal:  Eur J Rheumatol       Date:  2016-04-05

Review 7.  What effects might anti-TNFalpha treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFalpha in cardiovascular pathophysiology.

Authors:  W G Dixon; D P M Symmons
Journal:  Ann Rheum Dis       Date:  2007-01-24       Impact factor: 19.103

8.  Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis.

Authors:  M H Schiff; G R Burmester; J D Kent; A L Pangan; H Kupper; S B Fitzpatrick; C Donovan
Journal:  Ann Rheum Dis       Date:  2006-01-26       Impact factor: 19.103

Review 9.  TNFalpha blockade in human diseases: an overview of efficacy and safety.

Authors:  Jan Lin; David Ziring; Sheetal Desai; Sungjin Kim; Maida Wong; Yael Korin; Jonathan Braun; Elaine Reed; David Gjertson; Ram Raj Singh
Journal:  Clin Immunol       Date:  2007-10-04       Impact factor: 3.969

Review 10.  Biologics and heart failure in rheumatoid arthritis: are we any wiser?

Authors:  Maria I Danila; Nivedita M Patkar; Jeffrey R Curtis; Kenneth G Saag; Gim Gee Teng
Journal:  Curr Opin Rheumatol       Date:  2008-05       Impact factor: 5.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.